Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fanapt Pharmacogenetic Data Suggestive But Not Conclusive, FDA Finds

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA's review of the pharmacogenetic data in Vanda's NDA for Fanapt (iloperidone) suggests that sponsors should be prepared for the agency to require significant clinical evaluation before including pharmacogenetic criteria in labeling

You may also be interested in...



No Comparison: Viibryd’s Path Of Least Resistance Through FDA Could Mean Rocky Marketing

FDA’s statutory neutrality on comparative effectiveness in drug approval decisions both helped and held back Viibryd (vilazodone), now owned by Forest Laboratories. Because approval requires only that a candidate proves superiority to placebo, not to any existing treatments, the antidepressant entered a highly competitive, crowded market with statistically significant but commercially unremarkable efficacy.

No Comparison: Viibryd’s Path Of Least Resistance Through FDA Could Mean Rocky Marketing

FDA’s statutory neutrality on comparative effectiveness in drug approval decisions both helped and held back Viibryd (vilazodone), now owned by Forest Laboratories. Because approval requires only that a candidate proves superiority to placebo, not to any existing treatments, the antidepressant entered a highly competitive, crowded market with statistically significant but commercially unremarkable efficacy.

Pooled Antipsychotic Data Will Be Mined For Early Response Signals

A consortium of international drug companies hopes to leverage their pooled schizophrenia data into a means of determining which patient subgroups are most likely to respond to treatment during clinical trials.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS004210

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel